Regulus Therapeutics
RGLS
#7008
Rank
A$0.81 B
Marketcap
A$11.76
Share price
0.00%
Change (1 day)
363.86%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -A$72.73 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -A$66.56 Million a decrease over its 2023 earnings that were of -A$42.41 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -A$72.73 Million9.26%
2024 -A$66.56 Million56.97%
2023 -A$42.41 Million6.51%
2022 -A$39.82 Million2.53%
2021 -A$38.83 Million93.59%
2020 -A$20.06 Million-15.41%
2019 -A$23.72 Million-64.46%
2018 -A$66.71 Million-33.26%
2017 -A$99.96 Million-13.98%
2016 -A$0.12 Billion44.77%
2015 -A$80.27 Million-1.63%
2014 -A$81.6 Million203.6%
2013 -A$26.88 Million8.65%
2012 -A$24.74 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
A$11.09 B-16,333.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
A$2.24 B-3,381.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$13.43 B-19,767.29%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$20.32 B-29,845.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
A$14.25 B-20,964.39%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-A$0.16 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-A$0.17 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
A$0.82 B-1,313.98%๐Ÿ‡บ๐Ÿ‡ธ USA